Advocate Group’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.9M Buy
126,604
+14,942
+13% +$1.21M 1.49% 23
2026
Q1
$9.68M Sell
111,662
-83
-0.1% -$7.95K 1.51% 23
2025
Q4
$10.7M Sell
111,745
-2,548
-2% -$248K 1.74% 14
2025
Q3
$10.9M Buy
114,293
+1,737
+2% +$160K 1.79% 15
2025
Q2
$9.81M Buy
112,556
+2,525
+2% +$214K 1.75% 16
2025
Q1
$9.89M Buy
110,031
+3,255
+3% +$291K 1.8% 12
2024
Q4
$8.53M Buy
106,776
+4,897
+5% +$424K 1.61% 21
2024
Q3
$9.17M Buy
101,879
+4,576
+5% +$385K 1.66% 17
2024
Q2
$7.66M Buy
97,303
+4,522
+5% +$371K 1.54% 24
2024
Q1
$8.09M Buy
92,781
+4,922
+6% +$420K 1.61% 21
2023
Q4
$7.24M Buy
87,859
+7,479
+9% +$570K 1.55% 19
2023
Q3
$6.3M Buy
80,380
+5,622
+8% +$471K 1.46% 22
2023
Q2
$6.59M Buy
74,758
+10,938
+17% +$942K 1.45% 24
2023
Q1
$5.15M Buy
63,820
+12,072
+23% +$984K 1.12% 37
2022
Q4
$4.02M Sell
51,748
-5,549
-10% -$450K 0.87% 49
2022
Q3
$4.63M Buy
57,297
+796
+1% +$71.5K 1.14% 36
2022
Q2
$5.07M Buy
+56,501
New +$5.72M 1.18% 37

Other funds holding MDT

Advocate Group's MDT Position: Q2 2026 in Review

Advocate Group increased its Medtronic (MDT) stake by 13% in Q2 2026, buying an estimated $1.21M and bringing the position to 126,604 shares worth $9.9M. The position accounts for 1.49% of the portfolio, ranked #23.

Advocate Group first reported a position in MDT in Q2 2022 and has held it in 17 quarters since. The position peaked at $10.9M in Q3 2025. 961 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • Advocate Group held 126,604 shares of Medtronic worth $9.9M as of Q2 2026.
  • Advocate Group bought 14,942 Medtronic shares in Q2 2026, an estimated $1.21M.
  • Medtronic made up 1.49% of Advocate Group's portfolio in Q2 2026, its #23 holding.
  • Advocate Group first reported a position in Medtronic in Q2 2022 and has held it in 17 quarters since.
  • Advocate Group's Medtronic position peaked at $10.9M in Q3 2025.
  • 961 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Advocate Group's 13F filing for Q2 2026, filed 17 Jul 2026.